Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Am J Phys Med Rehabil ; 103(3): 194-202, 2024 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-37816223

RESUMO

OBJECTIVE: This study aimed to investigate the effects of an 8-wk face-to-face rehabilitation program on subjects with persistent symptoms of COVID-19 compared with a remote monitoring group. DESIGN: This is clinical, nonrandomized, controlled, and open study. The face-to-face supervised rehabilitation lasted eight consecutive weeks, twice a week. The remote monitoring group received health guidance. The allocation was carried out by preference because of the emergency period without vaccination during the pandemic. Fatigue, dyspnea (Pulmonary Functional Status and Dyspnea Questionnaire), and exercise capacity (Incremental Shuttle Walk Test) were the primary outcome measures. Lung function, functional status (Post-COVID-19 Functional Status), symptoms of anxiety and depression (Hospital Anxiety and Depression Scale), attention (d2-R), memory (Rey's Auditory-Verbal Learning Test), handgrip strength, and knee extensor strength were secondary outcome measures. RESULTS: Thirty-seven subjects (24.3% hospitalized) completed the baseline and final assessment, rehabilitation ( n = 22, 40.8 [SD, 10.0] yrs, 54.5% female), or remote guidance ( n = 15, 45.4 [SD, 10.5] yrs, 40% female). Both groups showed improved fatigue and exercise capacity. Exercise rehabilitation improved dyspnea, anxiety, attention, and short-term memory. CONCLUSIONS: Rehabilitation is essential for dyspnea in subjects with persistent symptoms of COVID-19 while fatigue naturally reverses.


Assuntos
COVID-19 , Doença Pulmonar Obstrutiva Crônica , Feminino , Humanos , Masculino , Brasil/epidemiologia , COVID-19/complicações , Dispneia/etiologia , Tolerância ao Exercício , Fadiga/etiologia , Força da Mão , Doença Pulmonar Obstrutiva Crônica/reabilitação , Qualidade de Vida , Adulto , Pessoa de Meia-Idade
2.
Psicol. ciênc. prof ; 42: e235853, 2022. tab
Artigo em Português | LILACS, Index Psicologia - Periódicos | ID: biblio-1360644

RESUMO

O metilfenidato é um fármaco indicado no tratamento do transtorno de déficit de atenção e hiperatividade (TDAH) e da narcolepsia. Atua no sistema nervoso central inibindo a recaptação de dopamina e noradrenalina, o que provoca um efeito psicoestimulante. Estudos anteriores demonstraram um aumento no consumo da droga por indivíduos saudáveis que buscam aprimoramento cognitivo. O objetivo deste estudo foi investigar a relação entre o uso não prescrito de metilfenidato e o desempenho acadêmico de estudantes de medicina de uma universidade do sul de Santa Catarina. Trata-se de uma pesquisa descritiva de caráter quantitativo. Participaram da pesquisa 243 acadêmicos do segundo ao oitavo semestre do curso de medicina; os dados foram coletados por meio de um questionário e analisados com ajuda do software SPSS versão 21.0. A prevalência de uso não prescrito do metilfenidato foi de 2,9%, enquanto 17,3% dos pesquisados afirmaram já ter utilizado o medicamento alguma vez na vida. As motivações para consumo mais citadas foram melhorar o desempenho cognitivo (10%) e ficar acordado por mais tempo (4,1%), e a forma de obtenção mais comum foi por meio de amigos (56,5%). O psicoestimulante não apresentou efeitos de aprimoramento cognitivo, uma vez que participantes que nunca utilizaram o fármaco apresentaram um desempenho acadêmico superior (8,80) se comparados àqueles que usam (7,92) ou já usaram (8,01). Os resultados corroboram a hipótese de efeito relacionado a sensações de bem-estar em pessoas saudáveis, o que torna preocupante a injustificada exposição aos efeitos adversos da droga. Ressalta-se a necessidade de ações que visem à promoção de saúde mental aos universitários.(AU)


Methylphenidate is a drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It acts on the central nervous system by inhibiting dopamine and norepinephrine reuptake, causing a psychostimulant effect. Previous studies have shown an increase in drug use by healthy individuals seeking cognitive enhancement. This study aimed to investigate the relationship between non-prescribed methylphenidate use and academic performance of medical students of a university in southern Santa Catarina. It is quantitative descriptive study. A total of 243 students from the second to the eighth semester of the medicine school participated in the research; data were collected by using a questionnaire and analyzed with the software SPSS Version 21.0. The prevalence of non-prescribed methylphenidate use was 2.9% and 17.3% of respondents said they had used the drug once in their lifetime. The most cited motivations for consumption were improving cognitive performance (10%) and staying awake longer (4.1%), with the most common way of obtention being through friends (56.5%). The psychostimulant had no cognitive enhancement effects since participants who never used the drug had a higher academic performance (8.80) compared with those who use (7.92) or have used it (8.01). The results corroborate the hypothesis of an effect related to feelings of well-being in healthy people, thus making the unjustified exposure to the adverse effects of the drug concerning. We emphasize the need for actions aimed at promoting mental health to university students.(AU)


El metilfenidato es un medicamento indicado para el tratamiento del trastorno por déficit de atención e hiperactividad (TDAH) y de la narcolepsia. Actúa sobre el sistema nervioso central al inhibir la reabsorción de dopamina y norepinefrina, causando un efecto psicoestimulante. Estudios anteriores han demostrado un aumento del consumo de este medicamento por personas sanas que buscan una mejora cognitiva. El objetivo de este estudio fue investigar la relación entre el uso no prescrito de metilfenidato y el rendimiento académico de los estudiantes de medicina de una universidad en el sur de Santa Catarina (Brasil). Se trató de una investigación cuantitativa descriptiva. Participaron en la investigación 243 estudiantes del segundo al octavo semestre del curso de medicina; los datos se recolectaron mediante un cuestionario y se analizaron con la ayuda del software SPSS, versión 21.0. La prevalencia del uso no prescrito de metilfenidato fue del 2,9%, y el 17,3% de los encuestados dijeron que habían usado el medicamento en algún momento de sus vidas. Las motivaciones de consumo más citadas fueron: mejorar el rendimiento cognitivo (10%) y permanecer despierto por más tiempo (4,1%), y la forma más común de obtenerlo fue con los amigos (56,5%). El psicoestimulante no tuvo ningún efecto de mejora cognitiva, ya que los participantes que nunca lo usaron tuvieron un rendimiento académico superior (8,80) en comparación con aquellos que lo usan (7,92) o lo han usado (8,01). Los resultados corroboraron la hipótesis de un efecto relacionado con los sentimientos de bienestar en personas sanas, lo que provoca una exposición injustificada a los efectos adversos de este fármaco. Se enfatiza la necesidad de acciones dirigidas a promover la salud mental de los estudiantes universitarios.(AU)


Assuntos
Humanos , Masculino , Feminino , Adulto Jovem , Estudantes de Medicina , Inteligência , Metilfenidato , Pesquisa , Atenção , Transtorno do Deficit de Atenção com Hiperatividade , Instituições Acadêmicas , Preparações Farmacêuticas , Dopamina , Saúde Mental , Vida , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Eficiência , Emoções , Desempenho Acadêmico , Medicina
3.
Acta Neuropsychiatr ; 26(1): 43-50, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25142099

RESUMO

OBJECTIVE: Cognitive deficits in schizophrenia play a crucial role in its clinical manifestation and seem to be related to changes in the cholinergic system, specifically the action of acetylcholinesterase (AChE). Considering this context, the aim of this study was to evaluate the chronic effects of ketamine in the activity of AChE, as well as in behavioural parameters involving learning and memory. METHODS: The ketamine was administered for 7 days. A duration of 24 h after the last injection, the animals were submitted to behavioural tests. The activity of AChE in prefrontal cortex, hippocampus and striatum was measured at different times after the last injection (1, 3, 6 and 24 h). RESULTS: The results indicate that ketamine did not affect locomotor activity and stereotypical movements. However, a cognitive deficit was observed in these animals by examining their behaviour in inhibitory avoidance. In addition, an increase in AChE activity was observed in all structures analysed 1, 3 and 6 h after the last injection. Differently, serum activity of AChE was similar between groups. CONCLUSION: Chronic administration of ketamine in an animal model of schizophrenia generates increased AChE levels in different brain tissues of rats that lead to cognitive deficits. Therefore, further studies are needed to elucidate the complex mechanisms associated with schizophrenia.


Assuntos
Acetilcolinesterase/metabolismo , Encéfalo/enzimologia , Ketamina/toxicidade , Atividade Motora/efeitos dos fármacos , Esquizofrenia/enzimologia , Animais , Corpo Estriado/enzimologia , Modelos Animais de Doenças , Hipocampo/enzimologia , Masculino , Memória/efeitos dos fármacos , Córtex Pré-Frontal/enzimologia , Ratos , Ratos Wistar , Esquizofrenia/induzido quimicamente
4.
Braz J Psychiatry ; 34(2): 168-75, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22729413

RESUMO

OBJECTIVES: Olanzapine, an atypical antipsychotic drug with affinities for dopamine, serotonin, and histamine binding sites appears to be associated with substantial weight gain and metabolic alterations. The aim of this study was to evaluate weight gain and metabolic alterations in rats treated with olanzapine on a hypercaloric diet. METHODS: We used 40 rats divided into 4 groups: Group 1, standard food and water conditions (control); Group 2, standard diet plus olanzapine; Group 3, cafeteria diet (hypercaloric); and Group 4, olanzapine plus cafeteria diet. Olanzapine was administered by gavage at a dose of 3 mg/kg for 9 weeks. RESULTS There were no significant changes in the cholesterol levels in any group. Glucose levels increased in Group 3 by the fourth week. Triglyceride levels were altered in group 2 toward the end of the experiment. Leptin levels decreased in Groups 2 and 4. Complex II activity in the muscles and liver was altered in Group 2 (muscle), and Groups 2, 3, and 4 (liver). Complex IV activity was altered only in the liver in Group 2, without significant alterations within the muscles. CONCLUSION: These results suggest that olanzapine is correlated with weight gain and the risks associated with obesity.


Assuntos
Antipsicóticos/efeitos adversos , Benzodiazepinas/efeitos adversos , Metabolismo Energético/efeitos dos fármacos , Leptina/sangue , Aumento de Peso/efeitos dos fármacos , Animais , Masculino , Olanzapina , Distribuição Aleatória , Ratos , Ratos Wistar
5.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 34(2): 168-175, June 2012. ilus, tab
Artigo em Inglês | LILACS | ID: lil-638698

RESUMO

OBJECTIVES: Olanzapine, an atypical antipsychotic drug with affinities for dopamine, serotonin, and histamine binding sites appears to be associated with substantial weight gain and metabolic alterations. The aim of this study was to evaluate weight gain and metabolic alterations in rats treated with olanzapine on a hypercaloric diet. METHODS: We used 40 rats divided into 4 groups: Group 1, standard food and water conditions (control); Group 2, standard diet plus olanzapine; Group 3, cafeteria diet (hypercaloric); and Group 4, olanzapine plus cafeteria diet. Olanzapine was administered by gavage at a dose of 3 mg/kg for 9 weeks. RESULTS There were no significant changes in the cholesterol levels in any group. Glucose levels increased in Group 3 by the fourth week. Triglyceride levels were altered in group 2 toward the end of the experiment. Leptin levels decreased in Groups 2 and 4. Complex II activity in the muscles and liver was altered in Group 2 (muscle), and Groups 2, 3, and 4 (liver). Complex IV activity was altered only in the liver in Group 2, without significant alterations within the muscles. CONCLUSION: These results suggest that olanzapine is correlated with weight gain and the risks associated with obesity.


OBJETIVOS: A olanzapina, uma droga antipsicótica atípica com afinidade por locais de ligação de dopamina, serotonina e histamina, parece se associar a um ganho de peso e a alterações metabólicas consideráveis. O objetivo desse estudo foi avaliar o ganho de peso e as alterações metabólicas em ratos tratados com olanzapina numa dieta hipercalórica. MÉTODOS: Usamos 40 ratos divididos em 4 grupos: Grupo 1, condições padrão de alimento e água (controle); Grupo 2, dieta padrão mais olanzapina; Grupo 3, dieta hipercalórica; e Grupo 4, olanzapina mais dieta hipercalórica. Olanzapina foi administrada por gavagem a uma dose de 3 mg/kg por 9 semanas. RESULTADOS: Não houve alterações significativas nos níveis de colesterol em qualquer um dos grupos. Os níveis de glicose aumentaram no Grupo 3 por volta da quarta semana. Os níveis de triglicerídeos estavam alterados no Grupo 2 ao final do experimento. Os níveis de leptina diminuíram nos Grupos 2 e 4. A atividade do complexo II nos músculos e no fígado se alterou no Grupo 2 (músculos) e nos Grupos 2, 3 e 4 (fígado). A atividade do complexo IV se alterou apenas no fígado no Grupo 2, sem alterações significativas nos músculos. CONCLUSÃO: Esses resultados sugerem que olanzapina se correlaciona ao ganho de peso e aos riscos associados à obesidade.


Assuntos
Animais , Masculino , Ratos , Antipsicóticos/efeitos adversos , Benzodiazepinas/efeitos adversos , Metabolismo Energético/efeitos dos fármacos , Leptina/sangue , Aumento de Peso/efeitos dos fármacos , Distribuição Aleatória , Ratos Wistar
6.
Metab Brain Dis ; 26(3): 229-36, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21789567

RESUMO

Alzheimer disease (AD) is a progressive neurodegenerative disease associated with cognitive impairment in multiple domains, such as memory and executive functions. Studies reveal damage in the electron transport chain of patients with AD, suggesting that this mitochondrial dysfunction plays an important role in the pathophysiology of the disease. Blood samples were taken from patients with AD (n = 20) and older subjects without dementia (n = 40) to evaluate the activity of complexes I, II, II-III, and IV of the mitochondrial respiratory chain in isolated lymphocytes. Results from the patient and control groups were compared. The activity of complexes II and IV was increased among patients compared to the control group. No significant difference was observed between controls who were not using psychotropic medication and patients. Our findings point out a mechanism of cellular compensation in which the mitochondrial respiratory chain requires an increase in electron transport to supply the energy needed for cellular functioning. Additional studies are needed to better clarify the mechanisms involved in the mitochondrial dynamics of AD.


Assuntos
Doença de Alzheimer/metabolismo , Complexo II de Transporte de Elétrons/metabolismo , Complexo IV da Cadeia de Transporte de Elétrons/metabolismo , Transporte de Elétrons/fisiologia , Linfócitos/metabolismo , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Complexo I de Transporte de Elétrons/metabolismo , Complexo III da Cadeia de Transporte de Elétrons/metabolismo , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mitocôndrias/metabolismo
7.
Metab Brain Dis ; 26(1): 69-77, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21331561

RESUMO

Evidence from the literature indicates that mitochondrial dysfunction occurs in schizophrenia and other psychiatric disorders. To produce an animal model that simulates psychotic symptoms analogous to those seen in schizophrenic patients, sub-anesthetic doses of N-methyl-D-aspartate (NMDA) receptor antagonists (such as ketamine) have been used. The aim of this study was to evaluate behavioral changes and mitochondrial dysfunction in rats administered ketamine for 7 consecutive days. Behavioral evaluation was performed using an activity monitor 1, 3 and 6 h after the last injection. The activities of mitochondrial respiratory chain complexes I, II, I-III and IV in multiple brain regions (prefrontal cortex, striatum and hippocampus) were also evaluated. Our results showed that hyperlocomotion occurred in the ketamine group 1 and 3 h after the last injection. Stereotypic movements were elevated only when animals were evaluated 1 h after receiving ketamine. In addition, we found that ketamine administration affects the respiratory chain, altering the activity of respiratory chain complexes in the striatum and hippocampus after 1 h, those in the prefrontal cortex and hippocampus after 3 h and those in the prefrontal cortex and striatum 6 h after the last administration of ketamine. These findings suggest that ketamine alters the behavior of rats and changes the activity of respiratory chain complexes in multiple brain regions at different time points.


Assuntos
Transporte de Elétrons/efeitos dos fármacos , Ketamina/farmacologia , Mitocôndrias , Receptores de N-Metil-D-Aspartato/metabolismo , Esquizofrenia/fisiopatologia , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/fisiopatologia , Modelos Animais de Doenças , Complexo I de Transporte de Elétrons/metabolismo , Complexo II de Transporte de Elétrons/metabolismo , Complexo III da Cadeia de Transporte de Elétrons/metabolismo , Complexo IV da Cadeia de Transporte de Elétrons/metabolismo , Humanos , Masculino , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/enzimologia , Ratos , Ratos Wistar , Receptores de N-Metil-D-Aspartato/antagonistas & inibidores , Fatores de Tempo , Distribuição Tecidual
8.
Oxid Med Cell Longev ; 3(6): 421-7, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21270541

RESUMO

Schizophrenia is a debilitating mental disorder characterized by positive (delusions, hallucinations, disorganized speech) and negative (affective flattering, avolition, and social withdrawal) symptoms as well as cognitive deficits. The frequency, severity, and topography characterize the disorder as heterogeneous, the pathophysiology of schizophrenia is poorly understood. Sub-anesthetic doses of ketamine produce hyperactivity, stereotypy, and abnormal social interaction and it is used as a model of schizophrenia. In this study, we induced an animal model by acute sub-anesthetic doses of ketamine and tested different behavioral parameters. We also evaluated the activity of creatine kinase (CK) in brain of rats treated with ketamine. Our results demonstrated that administration of 10, 25 and 50 mg/kg of ketamine induced an increase of covered distance in habituated and non-habituated rats to the behavioral apparatus. Ketamine administration induced significant social deficits and stereotypic behavioral in all doses tested. Finally we evaluated the effect of different doses of ketamine on creatinine kinase (CK) activity and we observed that CK activity is increased inspecific regions of the brain. Our study suggests that our animal model may be used as a model of schizophrenia and that cerebral energy metabolism might be altered in the brain of schizophrenic patients, probably leading to alterations that might be involved in the pathogenesis of schizophrenia.


Assuntos
Creatina Quinase/metabolismo , Esquizofrenia/enzimologia , Animais , Comportamento Animal/efeitos dos fármacos , Encéfalo/metabolismo , Modelos Animais de Doenças , Ketamina , Masculino , Atividade Motora/efeitos dos fármacos , Ratos , Ratos Wistar , Esquizofrenia/induzido quimicamente , Esquizofrenia/fisiopatologia , Psicologia do Esquizofrênico
9.
Psic ; 7(1): 69-77, Jan.-Jun. 2006. graf, tab
Artigo em Português | Index Psicologia - Periódicos | ID: psi-42142

RESUMO

O presente estudo buscou evidencias de validade entre o R1- Teste não-verbal de inteligência e o Teste Conciso de Raciocínio, cujos manuais indicam medir o fator g, e ambos construídos para pessoas que pretendem adquirir suas carteiras de motorista. O estudo contou com 65 voluntários, com idades entre 18-48 anos (M=24,36) que participavam do processo para a aquisição da Carteira de Habilitação Nacional. Os coeficientes de correlação possibilitaram inferir que uma parte substancial da variância de ambos os testes foi comum, indicativo de que mediriam uma alta quantidade de um mesmo mecanismo psicológico. Assim, foi possível considerar que essa relação era indicativa de uma evidência de validade de constructo. Finalmente, foi constatado que o R1 discriminou apenas no intervalo de 20-40 pontos, diferentemente do TCR que proporcionou uma distribuição ao longo de sua extensão(AU)


The present study searched for evidence of validity between the R1- Teste não-verbal de inteligência and the Teste Conciso de Raciocínio, whose manuals indicate to measure the g factor, and both developed for people which intend to obtain their driver licenses. 65 volunteers, aged from 18 to 48 years (M=24.36), participating in the process for driver licenses were studied. The correlation coefficients make possible to infer that a substantial part of the variance of both the tests was common, indicating that they would measure a high amount of the same psychological mechanism. Thus, it was possible to consider that this relation was suggestive of an evidence of construct validity. Finally, it was evidenced that the R1 discriminated only for the range from 20 to 40 scores, and the TCR, however, provided a distribution in all its range(AU)

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...